Dataset Information

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

ABSTRACT: Increased transcription of ribosomal RNA genes (rDNA) by RNA Polymerase I is a common feature of human cancer, but whether it is required for the malignant phenotype remains unclear. We show that rDNA transcription can be therapeutically targeted with the small molecule CX-5461 to selectively kill B-lymphoma cells in vivo while maintaining a viable wild-type B cell population. The therapeutic effect is a consequence of nucleolar disruption and activation of p53-dependent apoptotic signaling. Human leukemia and lymphoma cell lines also show high sensitivity to inhibition of rDNA transcription that is dependent on p53 mutational status. These results identify selective inhibition of rDNA transcription as a therapeutic strategy for the cancer specific activation of p53 and treatment of hematologic malignancies.

SUBMITTER: Bywater MJ

PROVIDER: S-EPMC3749732 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

Bywater Megan J MJ Poortinga Gretchen G Sanij Elaine E Hein Nadine N Peck Abigail A Cullinane Carleen C Wall Meaghan M Cluse Leonie L Drygin Denis D Anderes Kenna K Huser Nanni N Proffitt Chris C Bliesath Joshua J Haddach Mustapha M Schwaebe Michael K MK Ryckman David M DM Rice William G WG Schmitt Clemens C Lowe Scott W SW Johnstone Ricky W RW Pearson Richard B RB McArthur Grant A GA Hannan Ross D RD

Cancer cell 20120701 1

Increased transcription of ribosomal RNA genes (rDNA) by RNA Polymerase I is a common feature of human cancer, but whether it is required for the malignant phenotype remains unclear. We show that rDNA transcription can be therapeutically targeted with the small molecule CX-5461 to selectively kill B-lymphoma cells in vivo while maintaining a viable wild-type B cell population. The therapeutic effect is a consequence of nucleolar disruption and activation of p53-dependent apoptotic signaling. Hum ...[more]

PMID: 22789538

Dataset Information

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

Publications

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma.
| S-EPMC7859402 | biostudies-literature

RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
| S-EPMC5695568 | biostudies-literature

Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.
| S-EPMC5233415 | biostudies-literature

Cancer therapeutic targeting using mutant-p53-specific siRNAs.
| S-EPMC6756012 | biostudies-literature

RNA polymerase I-specific subunits promote polymerase clustering to enhance the rRNA gene transcription cycle.
| S-EPMC3172167 | biostudies-literature

A novel breast cancer therapeutic strategy through Hsp90 inhibition and activation of the immune system
2023-09-21 | GSE168875 | GEO

Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy.
| S-EPMC6171565 | biostudies-literature

DDR1 inhibition as a new therapeutic strategy for colorectal cancer.
| S-EPMC6149912 | biostudies-literature

Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer.
| S-EPMC8037052 | biostudies-literature

Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair.
| S-EPMC8275734 | biostudies-literature